Appetitee-TRFNCT07505680
Time-restricted Feeding and Health
A study testing Time-Restricted Feeding in people with Appetite and Circadian Rhythm, run by Harokopio University at 1 site in Greece.
Trial summary
The purpose of this pilot, single-arm clinical trial is to assess the effects of time-restricted feeding on overall health, including body composition, glycemic and lipidemic profile, as well as appetite-regulating hormones, including glucagon-like peptides 1(GLP-1) oxyntomodulin, glucagon. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Appetite, Circadian Rhythm, Metabolic Health
- What is being tested?
- Time-Restricted Feeding
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteGreece
- Study dates
- 4 Jun 2025to 16 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy men or women aged 18-35 years
- Habitual daily eating window >10 hours
- Stable body weight over the past 3 months (< ±10% change)
- Able to provide informed consent independently
Who cannot join
- Night shift work more than once per week
- Presence of chronic diseases (e.g., cancer, renal or hepatic disease, inflammatory bowel disease, hypertension, diabetes, cognitive or psychiatric disorders)
- Eating disorders
- Use of medications affecting the intervention (e.g., corticosteroids, antidiabetics)
- Pregnancy or planning pregnancy within the next 12 months
- Diagnosis of insomnia
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Early Time-restricted Feeding in Metabolic Health - Differences Between Chronotypes.
The purpose of this pilot, single-arm clinical trial is to assess the effects of time-restricted feeding on overall health, including body composition, glycemic and lipidemic profile, as well as appetite-regulating hormones, including glucagon-like peptides 1(GLP-1) oxyntomodulin, glucagon. Additionally, the study aims to evaluate the impact of this dietary pattern on circadian rhythm parameters, including acrophase, mesor, and amplitude.
- Conditions
- Appetite, Circadian Rhythm, Metabolic Health, Body Weight Control, Glycemic and Insulinemic Response
- Being tested
- Time-Restricted Feeding
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Time-Restricted FeedingOther
Ad libitum food intake from 08:00 to 18:00, followed by fasting from 18:00 to 08:00 for four weeks. Outside the eating window, water and limited amounts (1-2 servings) of very low-calorie items (e.g., tea, diet soft drinks, coffee, chewing gum <4 kcal/serving) were permitted. The intervention focused exclusively on the timing of food intake and did not impose restrictions on the quantity or type of foods consumed.
| Study group | Role | What they receive |
|---|---|---|
| Time-Restricted Feeding | Other | Participants followed a four-week regimen of ad libitum food intake from 08:00 to 18:00, followed by a 14-hour fasting period until 08:00 the next day, while maintaining habitual physical activity and sleep patterns. Receives: Other: Time-Restricted Feeding |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes from baseline in appetite-regulating hormones , including GLP-1 in pg/mL, oxyntomodulin in pg/mL, and glucagon in pg/mL at week 4, measured by ELISA kits.
Participants arrived at the laboratory between 08:30 and 09:00. An antecubital catheter was placed, and five blood samples were collected at fasting (0 min) and at 30, 60, 90, and 120 minutes after consuming the test meal. The test meal consisted of 100 g of S-Core FLEX Compact Protein powder (40 g carbohydrate, 29 g protein, 19 g fat) dissolved in 250 mL of water, providing 475 kcal.
Measured: Baseline and Week 4
Secondary outcomes (3)
Changes from baseline in circadian rhythm parameters (acrophase in degrees of Celcious, mesor in time units, amplitude in degrees of Celcious) at week 4, measured through continouous measurements in skin termperature by a thermistor.
Participants wore a wireless skin temperature sensor (Thermochron iButton® DS1921-F5) on the palmar surface of the wrist of the non-dominant hand for 2 consecutive days. Circadian rhythmicity was analyzed using Cosinor analysis, which applies the least-squares method to fit the chronobiological data to cosine functions with predetermined periods of 12 and 24 hours.
Measured: Baseline and Week 4
Changes from baseline in Body Composition, namely fat free mass in kg and fat mass in kg
Participant's body composition measurement pre/post time restricted feeding protocol
Measured: Baseline and week 4
Changes from Baseline in Glycemic and Lipidemic Profile, assessed by photometry.
Biochemical measurements in blood.
Measured: Baseline and Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2026
- Study start4 Jun 2025
- Primary completion16 Dec 2025
- Study completion16 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AppetiteStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Harokopio University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Konstantinos Anastasiou, Harokopio University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07505680
- Sponsor's protocol ID
- Γ-1936/02-05-2025
- Acronym
- e-TRF
- Status last verified
- Mar 2026
- First submitted
- 15 Jan 2026
- Last updated
- 1 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Early Time-restricted Feeding in Metabolic Health - Differences Between Chronotypes.
- ClinicalTrials.gov ID
- NCT07505680
- Acronym / sponsor ID
- e-TRF / Γ-1936/02-05-2025
- Conditions
- Appetite, Circadian Rhythm, Metabolic Health, Body Weight Control, Glycemic and Insulinemic Response
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Harokopio UniversityUniversity, hospital or other
- Study start
- 4 Jun 2025 (actual)
- Primary completion
- 16 Dec 2025 (actual)
- Study completion
- 16 Dec 2025 (actual)
- First posted
- 1 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this pilot, single-arm clinical trial is to assess the effects of time-restricted feeding on overall health, including body composition, glycemic and lipidemic profile, as well as appetite-regulating hormones, including glucagon-like peptides 1(GLP-1) oxyntomodulin, glucagon. Additionally, the study aims to evaluate the impact of this dietary pattern on circadian rhythm parameters, including acrophase, mesor, and amplitude.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Time-Restricted Feeding | Other | Other: Time-Restricted FeedingParticipants followed a four-week regimen of ad libitum food intake from 08:00 to 18:00, followed by a 14-hour fasting period until 08:00 the next day, while maintaining habitual physical activity and sleep patterns. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy men or women aged 18-35 years
- Habitual daily eating window >10 hours
- Stable body weight over the past 3 months (< ±10% change)
- Able to provide informed consent independently
Key exclusion criteria (6 listed)
- Night shift work more than once per week
- Presence of chronic diseases (e.g., cancer, renal or hepatic disease, inflammatory bowel disease, hypertension, diabetes, cognitive or psychiatric disorders)
- Eating disorders
- Use of medications affecting the intervention (e.g., corticosteroids, antidiabetics)
- Pregnancy or planning pregnancy within the next 12 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Time-Restricted FeedingAd libitum food intake from 08:00 to 18:00, followed by fasting from 18:00 to 08:00 for four weeks. Outside the eating window, water and limited amounts (1-2 servings) of very low-calorie items (e.g., tea, diet soft drinks, coffee, chewing gum <4 kcal/serving) were permitted. The intervention focused exclusively on the timing of food intake and did not impose restrictions on the quantity or type of foods consumed. | Other | Time-Restricted Feeding |
Primary outcome
Changes from baseline in appetite-regulating hormones , including GLP-1 in pg/mL, oxyntomodulin in pg/mL, and glucagon in pg/mL at week 4, measured by ELISA kits.
Time frame: Baseline and Week 4
Participants arrived at the laboratory between 08:30 and 09:00. An antecubital catheter was placed, and five blood samples were collected at fasting (0 min) and at 30, 60, 90, and 120 minutes after consuming the test meal. The test meal consisted of 100 g of S-Core FLEX Compact Protein powder (40 g carbohydrate, 29 g protein, 19 g fat) dissolved in 250 mL of water, providing 475 kcal.
3 secondary outcomes
Changes from baseline in circadian rhythm parameters (acrophase in degrees of Celcious, mesor in time units, amplitude in degrees of Celcious) at week 4, measured through continouous measurements in skin termperature by a thermistor.
Time frame: Baseline and Week 4
Changes from baseline in Body Composition, namely fat free mass in kg and fat mass in kg
Time frame: Baseline and week 4
Changes from Baseline in Glycemic and Lipidemic Profile, assessed by photometry.
Time frame: Baseline and Week 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2026.
Related trials for Appetite
Active, not recruitingPhase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
Electric Stimulation Therapy, Obesity
Recruiting
A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia
Schizophrenia, Antipsychotic Induced Weight Gain
RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Overweight or Obesity
Not yet recruitingPhase 3
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
Overweight or Obesity Without Diabetes
Active, not recruiting
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
Overweight, Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Time-Restricted Feeding in people with Appetite and Circadian Rhythm, run by Harokopio University at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes from baseline in appetite-regulating hormones , including GLP-1 in pg/mL, oxyntomodulin in pg/mL, and glucagon in pg/mL at week 4, measured by ELISA kits. (time frame: Baseline and Week 4). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026.